Leukemia Clinical Trials in Boston

Showing 1021-1040 of 1,445 trials

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

NCT02661815

Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a possible treatment for this diagnosis.

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma

Dana-Farber Cancer Institute6 participantsStarted Jun 2016

Boston, Massachusetts, United States • Boston, Massachusetts, United States

No Longer Available< 1 mile

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

NCT03178071

This expanded access study has being designed following a demand from the FDA, given the increase in the number of request for single patient INDs for lorlatinib

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Pfizer

Sedona, Arizona, United States • Huntington Beach, California, United States • Irvine, California, United States +46 more locations

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Leukemia Trials in Other Cities

0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer

Study of Ramucirumab in Ovarian Cancer

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Evaluating for Contact Allergies in Patients With Chronic Urticaria

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

A Study in Non-Small Cell Lung Cancer

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

A Study LY2228820 for Recurrent Ovarian Cancer

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Other Conditions in Boston